PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 35 filers reported holding PROQR THRAPEUTICS N V in Q4 2014. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $952,000 | -4.7% | 309,700 | 0.0% | 0.00% | – |
| Q4 2017 | $999,000 | -33.5% | 309,700 | 0.0% | 0.00% | -100.0% |
| Q3 2017 | $1,502,000 | -6.7% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $1,610,000 | +3.9% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $1,549,000 | +2.0% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $1,518,000 | -26.5% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $2,066,000 | +37.8% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $1,499,000 | -0.8% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $1,511,000 | -43.8% | 309,700 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $2,688,000 | -40.4% | 309,700 | 0.0% | 0.00% | -50.0% |
| Q3 2015 | $4,512,000 | -1.6% | 309,700 | +12.6% | 0.00% | 0.0% |
| Q2 2015 | $4,584,000 | -23.8% | 275,000 | 0.0% | 0.00% | -33.3% |
| Q1 2015 | $6,017,000 | +1.0% | 275,000 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $5,959,000 | +26.1% | 275,000 | 0.0% | 0.00% | +50.0% |
| Q3 2014 | $4,727,000 | – | 275,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Privium Fund Management B.V. | 5,344,446 | $18,010,783 | 6.83% |
| M28 Capital Management LP | 1,910,600 | $7,069,220 | 6.74% |
| Opaleye Management Inc. | 1,460,000 | $5,402,000 | 1.88% |
| Ikarian Capital, LLC | 422,625 | $1,563,713 | 0.38% |
| Monaco Asset Management SAM | 165,000 | $610,500 | 0.18% |
| AWM Investment Company, Inc. | 166,667 | $616,668 | 0.09% |
| FRANKLIN STREET ADVISORS INC /NC | 150,000 | $555 | 0.05% |
| Atom Investors LP | 18,522 | $68,531 | 0.03% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3,625,467 | $13,414,228 | 0.03% |
| GSA CAPITAL PARTNERS LLP | 21,514 | $80 | 0.01% |